In addition, EGFR-mutation testing for pII and pIII stage NS-NSCLC patients is anticipated to become mandatory based on the results of the ADAURA study positioning the use of osimertinib as adjuvant therapy in this population [19]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.